Get all your news in one place.
100's of premium titles.
One app.
Start reading
MarketBeat
MarketBeat
Business
Jeffrey Neal Johnson

SHOCKING: Cellectis charts course for 2025 with boost from astrazeneca deal - What They Never Told You

[content-module:CompanyOverview|NASDAQ:CLLS]

Cellectis S.A. (NASDAQ: CLLS) is a clinical-stage biotechnology company focused on developing 'off-the-shelf' cancer immunotherapies using gene-editing technology.

Following a substantial strategic equity investment from AstraZeneca (NASDAQ: AZN) and a strengthened financial position reported in its full-year 2024 results, Cellectis has entered a potentially pivotal stage in its market narrative.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.